Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

Tumorigenic Properties of Iron Regulatory Protein 2 (IRP2) Mediated by Its Specific 73-Amino Acids Insert

(2010) Carmen Maffettone et al.   PLoS One

Regulation of Hepcidin and Iron-Overload Disease

(2009) Pauline L. Lee et al.   Annual Review of Pathology-Mechanisms of Disease

The Iron Chelator Dp44mT Causes DNA Damage and Selective Inhibition of Topoisomerase II  in Breast Cancer Cells

(2009) V. A. Rao et al.   CANCER RESEARCH

A Ferroportin Transcript that Lacks an Iron-Responsive Element Enables Duodenal and Erythroid Precursor Cells to Evade Translational Repression

(2009) De-Liang Zhang et al.   Cell Metabolism

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

RETRACTED: The Hepcidin-Binding Site on Ferroportin Is Evolutionarily Conserved

(2008) Ivana De Domenico et al.   Cell Metabolism

Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma

(2008) J. Boult et al.   CLINICAL CANCER RESEARCH

A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

(2007) Judith E. Karp et al.   LEUKEMIA RESEARCH